{"nctId":"NCT03738397","briefTitle":"A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis","startDateStruct":{"date":"2019-02-21","type":"ACTUAL"},"conditions":["Atopic Dermatitis"],"count":673,"armGroups":[{"label":"Upadacitinib 30 mg QD","type":"EXPERIMENTAL","interventionNames":["Biological: Upadacitinib","Drug: Placebo to dupilumab"]},{"label":"Dupilumab 300 mg EOW","type":"EXPERIMENTAL","interventionNames":["Biological: Dupilumab","Drug: Placebo to upadacitinib"]}],"interventions":[{"name":"Upadacitinib","otherNames":["ABT-494","RINVOQ®"]},{"name":"Dupilumab","otherNames":["Dupixent®"]},{"name":"Placebo to dupilumab","otherNames":[]},{"name":"Placebo to upadacitinib","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant has active moderate to severe atopic dermatitis (AD) defined by Eczema Area and Severity Index (EASI) ≥ 16, Investigator's Global Assessment (IGA) ≥ 3, ≥ 10% body surface area (BSA) of AD involvement at the Screening and Baseline Visits, and Baseline weekly average of daily Worst Pruritus NRS ≥ 4.\n* Participant is a candidate for systemic therapy or have recently required systemic therapy for AD.\n\nExclusion Criteria:\n\n* Participant has prior exposure to Janus Kinase (JAK) inhibitor.\n* Participant has prior exposure to dupilumab.\n* Participant is unable or unwilling to discontinue current AD treatments prior to the study.\n* Participant has requirement of prohibited medications during the study.\n* Participant has other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of AD lesions.\n* Female participant who is pregnant, breastfeeding, or considering pregnancy during the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"76 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving a 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 16","description":"EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \\[0\\], mild \\[1\\], moderate \\[2\\], or severe \\[3\\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).\n\nThe total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.6","spread":null},{"groupId":"OG001","value":"72.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 16","description":"The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).\n\nThe percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.58","spread":"1.986"},{"groupId":"OG001","value":"-67.78","spread":"1.906"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16","description":"EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \\[0\\], mild \\[1\\], moderate \\[2\\], or severe \\[3\\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).\n\nThe total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"28.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16","description":"EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \\[0\\], mild \\[1\\], moderate \\[2\\], or severe \\[3\\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).\n\nThe total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.3","spread":null},{"groupId":"OG001","value":"61.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 4","description":"The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).\n\nThe percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.39","spread":"2.288"},{"groupId":"OG001","value":"-60.41","spread":"2.204"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a 75% Reduction From Baseline in EASI Score at Week 2","description":"EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \\[0\\], mild \\[1\\], moderate \\[2\\], or severe \\[3\\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).\n\nThe total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":null},{"groupId":"OG001","value":"44.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 1","description":"The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).\n\nThe percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.94","spread":"1.831"},{"groupId":"OG001","value":"-31.96","spread":"1.772"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16","description":"The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","spread":null},{"groupId":"OG001","value":"56.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":331},"commonTop":["ACNE","DERMATITIS ATOPIC","NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION","HEADACHE"]}}}